Image credit: Canva
Acute lymphoblastic leukemia (ALL) is the most common cancer in children. Treatment is available for ALL, but if the disease returns, the survival rate drops to less than 50%. A clinical trial led by Nirali N. Shah, M.D., M.H.Sc., Lasker Clinical Research Scholar in the Pediatric Oncology Branch, is researching CAR T-cell therapy for children and young adults with ALL or other related B-cell lymphomas. The trial will take place at the NIH Clinical Center in Bethesda, Maryland, and there is no cost for participation.
For more information, please contact the Leukemia, Lymphoma, Transplantation and Cellular Therapy team at the NCI Pediatric Oncology Branch at (240) 760-6970 or NCILLTCT@nih.gov
Clinicaltrials.gov identifier: NCT05442515
NCI Protocol ID: 000324
Official Title: Phase 1/2 Dose Escalation Study of CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies
The Center for Cancer Research is NCI’s internal cancer center, a publicly funded organization working to improve the lives of cancer patients by solving important, challenging and neglected problems in cancer research and patient care. Highly trained physician-scientists develop and carry out clinical trials to create the medicines of tomorrow treating patients at the world’s largest dedicated research hospital on the campus of the National Institutes of Health in Bethesda, Maryland.
For more information on CCR clinical trials click here, and subscribe to have the latest CCR clinical trials sent directly to your inbox.
